ImmunoPrecise, Zymeworks partner on SARS-CoV-2 antibody

By The Science Advisory Board staff writers

September 17, 2020 -- ImmunoPrecise and Zymeworks announced that they have formed a research collaboration to develop a multispecific SARS-CoV-2 antibody.

Under the agreement, ImmunoPrecise will use Zymeworks' Azymetric and Efect platforms to further develop multiple COVID-19 monospecific antibody candidates by transforming them into bispecific and multispecific antibodies, the companies said.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.